Emergence and control of Fluoroquinolone Resistant Toxin A Negative Toxin B positive Clostridium difficile by Drudy, Denise et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles School of Biological Sciences 
2007 
Emergence and control of Fluoroquinolone Resistant Toxin A 
Negative Toxin B positive Clostridium difficile 
Denise Drudy 
Technological University Dublin, denise.drudy@tudublin.ie 
N. Harnedy 
S. Fanning 
L. Kyne 
Follow this and additional works at: https://arrow.tudublin.ie/scschbioart 
Recommended Citation 
Drudy, D. et al (2006). Emergence and control of Fluoroquinolone Resistant Toxin A Negative Toxin B 
positive Clostridium difficile. Infection Control and Hospital Epidemiology, 28(8), pp. 932-40. doi:10.1086/
519181 
This Article is brought to you for free and open access by 
the School of Biological Sciences at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
Infection Control
http://journals.cambridge.org/ICE
Additional services for Infection Control:
Email alerts: Click here
Subscriptions: Click here
Commercial reprints: Click here
Terms of use : Click here
Emergence and Control of Fluoroquinolone-Resistant, Toxin A–
Negative, Toxin B–Positive Clostridium difcile
Denise Drudy, Norma Harnedy, Séamus Fanning, Margaret Hannan and Lorraine Kyne
Infection Control / Volume 28 / Issue 08 / August 2007, pp 932 - 940
DOI: 10.1086/522269, Published online: 02 January 2015
Link to this article: http://journals.cambridge.org/abstract_S0195941700047056
How to cite this article:
Denise Drudy, Norma Harnedy, Séamus Fanning, Margaret Hannan and Lorraine Kyne (2007). Emergence and Control
of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difcile. Infection Control, 28, pp 932-940
doi:10.1086/522269
Request Permissions : Click here
Downloaded from http://journals.cambridge.org/ICE, IP address: 147.252.227.92 on 05 Feb 2015
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY AUGUST 2 0 0 7 , VOL. 2 8 , NO. 8 
O R I G I N A L A R T I C L E 
Emergence and Control of Fluoroquinolone-Resistant, 
Toxin A-Negative, Toxin B-Positive Clostridium difficile 
Denise Drudy, PhD; Norma Harnedy, MB, MRCPI; Seamus Fanning, PhD; 
Margaret Hannan, MD, MRCPI, MRCPath; Lorraine Kyne, MD, FRCPI, MPH 
BACKGROUND. Clostridium difficile is a major cause of infectious diarrhea in hospitalized patients. Between August 2003 and January 
2004, we experienced an increase in the incidence of C. difficile-associated disease. We describe the investigation into and management of 
the outbreak in this article. 
METHODS. A total of 73 consecutive patients with nosocomial C. difficile-associated diarrhea were identified. C. difficile isolates were 
characterized using toxin-specific enzyme immunoassays, a tissue-culture fibroblast cytotoxicity assay, polymerase chain reaction (PCR), 
and antimicrobial susceptibility tests. Rates of recurrence and of C. difficile colitis were recorded. Changes in antibiotic use and infection 
control policies were documented. 
RESULTS. The incidence of C. difficile-associated diarrhea peaked at 21 cases per 1,000 patient admissions. Of the C. difficile isolates 
recovered, 85 (95%) were identical toxin A-negative and toxin B-positive strains, corresponding to toxinotype VIII and PCR ribotype 017. 
All clonal isolates were resistant to multiple antibiotics, including ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin 
(minimum inhibitory concentrations [MICs] of greater than 32 /tg/mL) and erythromycin, clarithromycin, and clindamycin (MICs of 
greater than 256 /ng/mL). Recurrent C. rfi/^ci/e-associated disease occurred in 26 (36%) of the patients. At least 10 (14%) of the patients 
developed C. difficile colitis. Additional infection control measures introduced included the use of ward memos, a hand-hygiene awareness 
campaign, increased environmental cleaning, attention to prescribing practices for antibiotics, increased awareness of diarrheal illness, and 
early isolation of affected patients. Total use of fluoroquinolones did not change throughout the study period. Despite persistence of this 
toxin-variant strain, the incidence of C. difficile-associated disease in our institution decreased to fewer than 5 cases per 1,000 admissions. 
CONCLUSIONS. We report on the emergence of a fluoroquinolone- and clindamycin-resistant, toxin A-negative, and toxin B-positive 
strain of C. difficile associated with an outbreak of C. iij^ri/e-associated disease in our institution during a 6-month period. We found 
that careful attention to improvement of infection control interventions was the most important means of controlling this nosocomial 
pathogen. 
Infect Control Hosp Epidemiol 2007; 28:932-940 
Clostridium difficile is a common nosocomial pathogen and ing strains; the latter have been associated with more-severe 
a major cause of infectious diarrhea in hospitalized patients.1 disease and increased 30-day mortality.3 ,3,9-11 
Patients who receive antibiotic therapy are particularly sus- There is ongoing surveillance of all patients with CDAD 
ceptible to colonization with C. difficile and subsequent C. in our institution (The Mater Misericordiae University Hos-
dijficile-associated disease (CDAD).2 The risk of CDAD ap- pital; Dublin, Ireland). From 2001 to 2003, we experienced 
pears to be greater with certain antimicrobial agents.3"6 Recent winter peaks in the incidence of CDAD. From June 2001 to 
studies also suggest that the risk of CDAD increases if C. May 2002, levofloxocin was the first-line antimicrobial agent 
difficile is resistant to the administered antimicrobial.6 Resis- used for treatment of community-acquired pneumonia (CAP). 
tance to clindamycin and third-generation cephalosporins has This regimen was switched to cefuroxime plus clarithromycin 
been well documented; however, resistance to fluoroquino- in May 2002 because of concerns regarding the emergence 
lones, in particular the newer generation fluoroquinolones, of fluoroquinolone resistance in Streptococcus pneumoniae 
is a more recent development.6"8 Other worrisome trends in strains. However, the incidence of CDAD increased to 33 cases 
the epidemiology and pathogenesis of CDAD include the per 1,000 patient admissions in January 2003, resulting in the 
emergence of toxin-variant and hypervirulent toxin-produc- discontinuation of use of cefuroxime as a first-line agent for 
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CAP. Since April 2003, ofloxacin and benzylpenidllin have 
been the recommended first-line agents for CAP in our hos-
pital. Despite a decrease in the incidence of CD AD in May 
and June 2003, we became aware of an increase in the in-
cidence of CDAD in July 2003, when rates increased to more 
than 10 cases per 1,000 patient admissions. As part of an 
investigation into this outbreak, we performed cultures, typed 
strains, and performed antimicrobial-susceptibility testing on 
all isolates recovered from patients with CDAD during this 
period. We also documented rates of recurrence and of C. 
difficile colitis. 
M E T H O D S 
Study Population and Specimens 
The Mater Misericordiae University Hospital is a 570-bed, 
university-affiliated hospital in Dublin, Ireland, that serves a 
population of approximately 250,000, 11% of whom are aged 
65 years or older. There are 37 wards that are arranged into 
3-4 bays of 6 beds each. The average ratio of bathrooms to 
patients is 1:6. There are 84 single rooms, 39 of which are 
isolation rooms with anteroom and gowning facilities. Until 
2000, there were 2 infection control nurses; this number in-
creased to 4 in October 2002. 
We prospectively studied all newly diagnosed cases of nos-
ocomial CDAD between August 2003 and January 2004. Con-
secutive cases were identified by daily review of requests for 
assay of stool samples for C. difficile toxin (C. difficile Tox A/ 
B II enzyme-linked immunosorbent assay; Techlab) at the 
clinical microbiology laboratory. Patients with a prior history 
of CDAD at our institution or of CDAD that was not nos-
ocomially acquired were excluded from the study. A total of 
73 patients received a diagnosis of newly acquired nosocomial 
CDAD in this period. Patients were monitored until hospital 
discharge or death. For each patient, we recorded age, sex, 
Charlson comorbidity index,12 ward of admission, ward trans-
fers, antimicrobial agents received before onset of CDAD, all 
medications received, type of feeding regimen (oral feeding, 
tube feeding [by nasogastric, percutaneous gastrostomy, or 
jejunostomy tube], or total parenteral nutrition), serum al-
bumin levels, and white blood cell (WBC) count, and body 
temperature at the time of diagnosis of CDAD. Radiological 
or endoscopic investigations and specific anti-C. difficile ther-
apies were recorded. The clinical management after the onset 
of C. dij^ci/e-associated diarrhea was also documented. All 
additional infection control interventions and overall use of 
quinolone and cephalosporin antibiotics were recorded. 
Definitions 
Diarrhea was defined as a change in bowel habit with 3 or 
more unformed bowel movements for at least 2 days. C. 
dij^ci/e-associated diarrhea was defined as diarrhea not at-
tributed to any other cause and associated with a stool test 
positive for C. difficile toxin. Nosocomial C. difficile-associ-
ated diarrhea was defined as onset of C. difficile-associated 
diarrhea at least 48 hours after admission in a patient with 
no known previous history of CDAD. Recurrent CDAD was 
defined as the development of a new episode of CDAD con-
firmed by a positive results of C. difficile toxin test of stool 
during a 60-day follow-up period, after resolution of the ep-
isode that began at enrollment for at least 48 hours and after 
discontinuation of therapy with metronidazole or vanco-
mycin. Patients were classified as having C. difficile colitis on 
the basis of radiological or endosopic findings. 
Culture of Isolates 
C. difficile isolates were cultured on cyloserine-cefoxitin-fruc-
tose agar. Ninety C. difficile isolates were recovered from 64 
of 73 patients in this study and included a single isolate from 
each patient with 1 episode of diarrhea and 1 isolate repre-
senting each recurrent episode of diarrhea. We were unable 
to culture C. difficile from fecal specimens from 9 patients 
who tested positive for C. difficile toxin, because these patients 
had received metronidazole. However, these patients were still 
regarded as having tested positive for C. difficile in the epi-
demiological evaluation. 
Testing for C. difficile Toxins 
Toxin-specific immunoassays and cytotoxicity assays were 
used to detect toxin production after culture of C. difficile in 
brain-heart infusion broth for 72 hours. Toxins A and B were 
detected using the C. difficile Tox A/B II test (Techlab) and 
a tissue-culture cytotoxin assay (IMR-90; European Collec-
tion of Cell Cultures), respectively. 
Molecular Analysis of Isolates 
Genomic DNA was extracted from broth cultures of C. difficile 
and was quantified using the PicoGreen dsDNA Quantitation 
Kit (Molecular Probes). Polymerase chain reaction (PCR) re-
striction-fragment-length polymorphism (RFLP) "toxinotyp-
ing" was used to investigate all 90 C. difficile isolates.13,14 PCR 
ribotyping was performed in accordance with Stubbs et al.,15 
with some minor modifications. DNA fingerprints were stored 
as tagged-image-file-format (TIFF) files and were imported 
into BioNumerics software, version 4.0 (Applied Maths), with 
which dendrograms were created using the Dice coefficient 
and the unweighted pair-group method with arithmetic mean 
for cluster correlation. 
Antibiotic Susceptibility Testing 
Susceptibility to clindamycin, erythromycin, clarithromycin, 
ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, and mox-
ifloxacin was determined using the Etest (AB Biodisk). The 
minimum inhibitory concentration (MIC) was defined as 
the lowest concentration of antibiotic that prevented vis-
ible growth after 48 hours under anaerobic conditions and 
was interpreted according to Clinical and Laboratory Stan-
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TABLE i. Infection Control Interventions Used Before and During an Outbreak 
of Clostridium difficile Infection, by Year 
2002 
Daily surveillance of patients with gastrointestinal symptoms 
Purchase of new bedpans and commodes 
Additional ward cleaning 
Increase in the number of infection control personnel 
Introduction of Spiragel alcohol-based hand rub 
2003 
Distribution of ward memos 
Topic: hand hygiene 
Topic: early recognition of symptoms 
Topic: early isolation and cohorting on the basis of clinical symptoms 
Increased awareness and improved reporting of infection 
Lectures given at grand rounds and postgraduate lectures on infection control 
Hand-hygiene awareness campaign 
Enhanced environmental cleaning 
dards Institute (CLSI) breakpoints for clindamycin and 
trovofloxacin. 
Statistical Analysis 
Patients with severe CDAD and patients with nonsevere 
CDAD were compared. We used the x2 test or 2-tailed Fisher 
exact test, for categorical variables, and the Student t test or 
Wilcoxon rank-sum test, for continuous variables. We used 
multivariable logistic regression analyses to determine the in-
dependent predictors of severe disease. Age and sex were 
entered into each model, along with variables associated with 
the outcomes in univariate analyses ( P < .1). Only variables 
statistically significantly associated with the outcomes were 
included in the final models. All analyses were performed 
using the SAS software system, version 6.12 (SAS Institute). 
The a level was set at 0.05. All P values were 2 sided. 
RESULTS 
Incidence of CDAD 
From July 2003 through January 2004, there were 73 con-
secutive patients with CDAD and the corresponding C. dif-
ficile isolates analyzed. In September 2003, the incidence of 
CDAD peaked at 21 cases per 1,000 patient admissions. 
Heightened infection control measures were introduced and 
are outlined in Table 1 and below. These measures included 
recommendations that all antibiotic prescriptions should be 
reviewed with regard to specific start and stop dates and the 
necessity for antibiotic treatment. However, fluoroquinolone 
use was not discouraged, and ofloxacin and benzylpenicillin 
remained the first-line agents for treatment of CAP. By Jan-
uary 2004, incidence rates had returned to baseline levels and 
have remained stable up to the time that the analysis was 
FIGURE i. Annual time line showing the number of new patients with nosocomial Clostridium difficile-associated disease at Mater 
Misericordiae University Hospital in 2003 (gray boxes), 2004 (open boxes), and 2005 (black boxes), by month. 
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TABLE 2. Demographic and Clinical Characteristics of Patients With Clostridium difficile-
Associated Disease (CDAD) and Factors Associated With Severe Disease 
Patients with Patients with 
severe disease nonsevere disease All patients 
Characteristic (« = 10) (n = 63) {n = 73) P 
Male sex 7 (70) 26 (41) 33 (45) .09 
Age, years 
Mean ± SD 70.6 ± 14.6 72.7 ± 12.9 72.4 ± 13.0 
Median (range) 72.5 (38-88) 73 (29-95) 73 (29-95) NS 
Albumin level at admission, g/L 
Mean ± SD 29.9 ± 7.5 26.7 ± 6.5 27.1 ± 6.7 
Median (range) 29.5 (15-39) 28 (10-40) 28 (10-40) NS 
No. of antibiotics received before 
diagnosis of CDAD 
Mean ± SD 1.6 ± 0.7 1.6 ± 0.8 1.6 ± 0.8 
Median (range) 1.5 (1-3) 2 (0-3) 2 (0-3) NS 
Use of H2-receptor antagonists 1(10) 8(13) 9(12) NS 
Use of proton-pump inhibitors 5 (50) 39 (62) 44 (66) NS 
Intensive care unit 5 (50) 14 (22) 19 (26) .06 
Enteral feeding* 
Any 8 (80) 28 (44) 36 (49) .04 
Nasogastric feeding 8 (80) 26 (41) 34 (47) .02 
Charlson comorbidity index 
Mean ±SD 1.6 ± 1.7 4.5 ± 2.2 4.1 ± 2.3 
Median (range) 1.5 (0-5) 4 (0-12) 4 (0-12) .0003 
No. of comorbidities 
Mean ±SD 3.8 ± 1.9 6.1 ± 2.6 5.8 ± 2.6 
Median (range) 6 (1-12) 6 (1-12) 6 (0-12) .01 
NOTE. Data are no. (%) of patients, unless otherwise indicated. NS, not significant. 
" Feeding by nasogastric, percutaneous gastrostomy, or jejunostomy tube. 
completed (fewer than 5 cases per 1,000 patient admissions). 
Figure 1 shows all new cases of CDAD from 2003 through 
2005. 
Patient Characteristics and Outcomes 
The 73 patients affected were predominantly older white pa-
tients (median age, 73 years; range, 29-95 years). Most had 
clinically significant comorbid disease (median Charlson 
comorbidity score, 4; range, 0-12). Nineteen (26%) of the 
patients had severe underlying disease and spent some time 
in the intensive care unit (ICU) or high-dependency unit. 
Other baseline characteristics are shown in Table 2. 
Recurrent CDAD 
Of the 73 patients studied, 47 (64%) had a single episode of 
CDAD, 26 (36%) had a single recurrent episode of CDAD, 
and 7 (27%) had a second recurrence of CDAD during the 
outbreak period. All patients with recurrent CDAD were given 
treatment with antibiotics for 10 days. The frequency of re-
currence based on the type of treatment received was not 
examined. 
C. difficile Colitis 
At least 10 (14%) of the patients developed C. difficile colitis. 
All these patients showed evidence of colitis on abdominal 
computed tomography (CT) and had median WBC counts 
of 18.8 x 109 cells/L (range, 10.2 x 109-67.2 x 109 cells/L). 
One of these patients had a total colectomy for extensive 
pseudomembranous colitis. He survived the initial illness but 
subsequently died of unrelated causes. Of the other 9 patients 
with colitis, 4 died within 30 days after the onset of symptoms. 
Patients with severe disease were more likely to be male 
(P = .09) and to have severe underlying disease that neces-
sitated treatment in the ICU (P = .06) (Table 2). Although 
patients with more-severe disease had significantly lower 
scores on the Charlson comorbidity index (P = .0003), they 
were significantly more likely to have received enteral feeding 
(P = .04), in particular nasogastric feeding (P = .02), com-
pared with patients with less severe disease. The unadjusted 
odds ratio (OR) for severe disease associated with nasogastric 
feeding was 5.69 (95% confidence interval [CI], 1.12-29.00); 
however, in a multivariable logistic regression analysis, after 
adjustment for age and ICU stay, the OR was 4.69 (95% CI, 
0.81-28.62). No other independent predictors of severe dis-
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TABLE 3. Minimum Inhibitory Concentration (MIC) Values for Fluoroquinolone and Mac-
rolide Antibiotics for 85 Toxin-Variant Clostridium difficile Isolates (TV) and 5 Nonvariant 
Isolates (NV) 
Antibiotic, 
by class 
Fluoroquinolone 
Ofloxacin 
Ciprofloxacin 
Levofloxacin 
Moxifloxacin 
Gatifloxacin 
Macrolide 
Clindamycin 
Erythromycin 
Clarithromycin 
MIC50 
TV 
>32 
>32 
>32 
>32 
>32 
>256 
>256 
>256 
NV 
>32 
>32 
2 
0.25 
0.25 
4 
1.5 
0.5 
MIC, 
MIC90 
TV 
>32 
>32 
>32 
>32 
>32 
>256 
>256 
>256 
NV 
>32 
>32 
2 
0.5 
0.38 
4 
1.5 
0.5 
;ug/mLa 
Range 
TV 
>32 
>32 
>32 
>32 
>32 
>256 
>256 
>256 
NV 
>32 
>32 
1.5-2 
0.125-0.5 
0.25-0.38 
4 
1.5 
0.5 
Median 
TV 
>32 
>32 
>32 
>32 
>32 
>256 
>256 
>256 
NV 
>32 
>32 
2 
0.315 
0.25 
4 
1.5 
0.5 
NOTE. The 85 toxin-variant C. difficile isolates were negative for toxin A and positive for toxin B. The 
5 nonvariant isolates were positive for toxins A and B. MIC50, minimum inhibitory concentration required 
to inhibit growth of 50% of organisms; MIC9(), minimum inhibitory concentration required to inhibit 
growth of 90% of organisms. 
* MICs that were beyond the detection limits of the test used are so indicated: >32 /xg/mL for fluoro-
quinolones and >256 fig/mL for macrolides. 
ease were identified (Table 2). All patients with severe disease 
were infected with a fluoroquinolone-resistant toxin-variant 
C. difficile strain. 
Clinical Management of CDAD 
Whenever possible, use of antibiotics that predispose to 
CDAD was discontinued; however, many patients had con-
current bacterial infections that necessitated continued use 
of antibiotics. One patient with a single episode of CDAD 
received supportive care only. The remaining 72 patients were 
treated with metronidazole and/or vancomycin. Use of pro-
ton-pump inhibitors and H2-receptor antagonists was con-
tinued. Patients did not receive probiotics. Contact isolation 
was implemented when possible. With the rare exception of 
patients who could not be isolated, the ward was quarantined 
and no patients were admitted or discharged from that ward 
until they were symptom free for longer than 48 hours and 
until laboratory results confirmed no evidence of CDAD. If 
a case of CDAD was identified on a 6-bed unit, additional 
cases were sought. 
Trends in Antibiotic Use 
Sixty-nine (95%) of the patients received 1 or more anti-
microbial before the onset of CDAD (Table 3). Thirty (41%) 
of the patients received treatment with a single antibiotic, and 
30 patients (41%) received treatment with 2 antibiotics. Four 
patients did not receive any antibiotics while in the hospital. 
Of the patients with CDAD, 33 (27%) had received aug-
mentin and ofloxacin, alone or in combination. Trends in 
antibiotic prescribing since 2001 for individual fluoroquin-
olones and cephalosporins and for each class as a whole are 
shown in Figure 2. Total cephalosporin use in 2002 (16,992 
g) was almost twice that in 2001 (31,132 g). In contrast, total 
use of cephalosporins from 2003 through 2005 showed a 
downward trend, with 15,140 g used in 2003, 13,719 g used 
in 2004, and 11,696 g used in 2005. Total use of fluoroquin-
olones in 2002 through 2005 was almost half that in 2001 
(Figure 2). 
Infection Control Interventions 
A number of changes were introduced to the hospital's in-
fection control policy in 2002, after the first case of norovirus 
gastroenteritis was diagnosed in the hospital. These included 
the following measures: (1) an audit of all sinks, soaps, and 
moisturizers used throughout the hospital; (2) a switch from 
a liquid hand gel to alcohol-based hand rub (Spiragel; Spiral), 
to increase sanitizer coverage; (3) an increase in infection 
control personnel; and the resulting (4) increased patient sur-
veillance, in which every ward was visited on a daily basis 
and every patient with undiagnosed diarrhea was surveyed. 
For each patient with diarrhea, a surveillance form was filled 
out by the infection control staff, with a detailed medical 
history and information about prior diarrheal episodes, an-
tibiotics and/or stool looseners received, and prior CDAD. 
All patients with diarrhea had stool samples routinely 
screened for Salmonella, Shigella, and Campylobacter species, 
as well as Escherichia coli serotype 0157, C. difficile, and no-
rovirus. New equipment was purchased; this included new 
commodes that could be easily cleaned and bedpans that fit 
both the commodes and the standard bedpan washers. In 
addition, bedpan washers were monitored to ensure that the 
correct washing temperature was consistently reached. 
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During the outbreak in 2003, several additional infection 
control measures were included, along with heightened en-
forcement and awareness of existing measures. Efforts were 
increased for the early identification and isolation of patients 
with CDAD. During the outbreak period, a container of al-
cohol-based hand rub was placed at the end of the bed of 
every patient with diarrhea. Healthcare workers with minor 
contact with patients and clinically clean hands (according 
to World Healthcare Organization guidelines) used alcohol-
based hand rub to clean their hands between caring for dif-
ferent patients. When extensive patient contact had occurred, 
HCWs were encouraged to wash their hands with soap and 
water. A multifaceted education program was introduced, and 
a major emphasis was placed on education and awareness of 
this new hand-hygiene policy throughout the hospital. This 
included a hand-hygiene campaign that targeted existing staff, 
new staff, and patients. Lectures on hygiene were given by 
infection control staff and consultants at grand rounds, staff-
induction meetings, and meetings of the infection control 
committee. Regular random checks with the ultraviolet test 
for adequate hand hygiene were performed on staff through-
out the hospital. Enhanced measures to control the environ-
mental transmission of C. difficile were also introduced. These 
included increasing the frequency of environmental cleaning 
from once to twice daily with use of the standard chlorine-
releasing disinfectant (1,000 ppm); enhanced cleaning of pa-
tient furniture, in which armchairs were cleaned as part of 
daily cleaning procedure; and enhanced cleaning of shared 
equipment, such as sphygmomanometer cuffs for measuring 
blood pressure. Use of shared equipment was restricted to 
similarly affected patients if used by a patient with diarrhea. 
Molecular Analysis of C. difficile Isolates 
Ninety C. difficile isolates were cultured from 64 of the 73 
patients in this study. Sixty patients were infected with toxin 
A-negative, toxin B-positive C. difficile isolates, whereas 4 
patients were infected with toxin A-positive, toxin B-positive 
C. difficile isolates. All sample isolates were positive for C. 
difficile toxin B by use of the tissue-culture cytoxicity assay 
(data not shown). Eighty-five (95%) of the isolates induced 
a differential cytopathic effect, with complete rounding of the 
fibroblast body in comparison with wild-type cytopathic ef-
fect, in which protrusions remain attached to the cell body.16 
None of these isolates produced detectable toxin A (data not 
shown). Toxinotyping identified a 1.7-kb deletion located in 
the repeating domain of the tcdA gene in these isolates. PCR 
identified RFLPs in the A3, Bl, and B3 domains, and isolates 
were designated toxinotype VIII, in accordance with the 
scheme of Rupnik et al.14 The 5 remaining isolates carried 
the entire tcdA and tcdB genes, corresponding to toxinotype 
0. All 90 isolates were analyzed by 16S-23S PCR ribotyping, 
producing DNA banding patterns consisting of 10-14 bands, 
with a size range of approximately 100-1,000 bp. One major 
cluster of 85 toxin A-negative, toxin B-positive C. difficile 
isolates was identified on the basis of a quantitative analysis 
of the banding patterns obtained, and all isolates demon-
strated banding patterns indistinguishable from strain type 
1470 and PCR ribotype 017 (data not shown). 
Antibiotic Susceptibility Testing 
The MICs for the 90 C. difficile isolates from this study are 
shown in Table 3. All isolates negative for toxin A and positive 
for toxin B demonstrated a high level of resistance to the 5 
2001 2002 2003 2004 2005 
FIGURE 2. Fluoroquinolone and cephalosporin usage at Mater Misericordiae University Hospital, 2001-2005. Total use of fluoroquin-
olones (open triangles) and cephalosporins (black triangles) is overlaid as a line graph. 
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fluoroquinolones tested, with MICs of greater than 32 fig/ 
mL. Resistance to clindamycin, erythromycin, and clarith-
romycin was also identified, with MICs of greater than 256 
jiig/mL. In contrast, the MICs of the unrelated isolates positive 
for toxins A and B were markedly reduced for levofloxacin, 
moxifloxacin, and gatifloxacin, with median MICs of 3, 0.3, 
and 0.2 pig/mL, respectively. Likewise, these isolates positive 
for toxins A and B were up to 9-fold more susceptible to 
clindamycin, erythromycin, and clarithromycin, with median 
MICs of 4, 1.5, and 0.5 jug/mL, respectively. 
D I S C U S S I O N 
We experienced a significant increase in the incidence of 
CDAD at our institution over a 6-month period in 2003; 
there were 73 patients diagnosed with CDAD, at least 14% 
of whom had evidence of colitis. During this period, we saw 
the emergence of a toxin-variant clone (negative for toxin A 
and positive for toxin B) that was resistant to fluoroquino-
lones and macrolide, lincosamide, and streptogramin anti-
biotics. The trigger for the clonal expansion of this strain type 
is not known, but we speculate that it may have been the 
widespread use of fluoroquinolones and cephalosporins in 
our institution in the preceding years, 2001 and 2002. Control 
of this toxin-variant strain was achieved through infection 
control measures other than curtailing the use of fluoro-
quinolones and cephalosporins. The hand-hygiene policy was 
changed in 2002, when alcohol-based hand rub was intro-
duced, and was not associated with an increase in the inci-
dence of C. difficile infection, which is similar to findings 
reported by Boyce et al.17 and Gordin et al.18 Although the 
hand-hygiene policy was not altered with regard to the use 
of alcohol hand rub, heightened awareness and enforcement 
of this policy is likely to have contributed to control of this 
outbreak. 
Toxin-variant (toxin A-negative and toxin B-positive) C. 
difficile strains have been isolated in several countries world-
wide. Prevalence rates vary from 0.2% to 37% of isolates.19"22 
Although several sporadic cases of CDAD due to toxin-
variant strains have been reported, only 2 hospitals have 
previously documented outbreaks of infection with this strain 
type. Al-Barrak et al.23 were the first to report an outbreak 
of infection with a toxin-variant strain of C. difficile, in Can-
ada in 1998, in which 14 cases of toxin-variant CDAD were 
diagnosed. In that study, 5 (36%) of the patients had recurrent 
diarrhea, whereas 3 (20%) had severe colitis, associated with 
a 66% mortality rate. Kuijper et al.24 described an outbreak 
in The Netherlands in which 24 patients received a diagnosis 
of toxin-variant CDAD. Three patients (13%) had recurrent 
disease, and there were 7 patients with severe disease, with 1 
death (14%). The rate of recurrence of CDAD noted in our 
study (36%) and in other outbreaks due to toxin-variant 
strains are similar to recurrence rates reported by us and others 
for disease caused by isolates positive for toxins A and B.2 
The rate of severe disease documented in our study is 
higher than that reported elsewhere for nonvariant C. difficile. 
In an earlier prospective study of patients who acquired toxin 
A-positive, toxin B-positive C. difficile in Boston, we found 
that less than 5% developed severe pseudomembranous co-
litis.2 Because 95% of the isolates we found were toxin variant, 
we were unable to compare disease severity rates associated 
with variant and nonvariant strains in our hospital. The pro-
spective nature of our investigation into this outbreak did 
allow us to assess each patient closely for symptoms of severe 
disease. We used criteria for disease severity similar to those 
used by McEllistrem et al.11 in a recent investigation of a 
hospital outbreak of CDAD. In that study, the rate of severe 
disease was 16.3%, which is similar to the rate in our study 
(14%)." It is possible that we underestimated the rate of 
severe disease because the decision to investigate patients by 
use of CT was determined by the physician responsible for 
the healthcare provision to those patients and was generally 
reserved for sicker patients. We feel that it is unlikely that we 
overestimated the rate of severe disease, because in addition 
to having CT evidence of colitis, all patients classified as hav-
ing severe disease had markedly elevated WBC counts, ele-
vated temperatures, and abdominal pain or distension. 
We found that patients who developed more-severe disease 
had fewer comorbidities than did patients who developed 
less-severe disease. However, the former were sicker patients; 
50% of them were cared for in the ICU, and 80% of them 
received nasogastric feeding. Although nasogastric feeding 
was significantly associated with more-severe disease on uni-
variate analysis, this was a marker for severe underlying dis-
ease, since the association lost significance once we controlled 
for age and ICU stay. A limitation of our study was that 
patients were studied after their diagnosis of CDAD was con-
firmed by laboratory testing. Consequently we were unable 
to assess the severity of underlying diagnosis before the onset 
of symptoms. We showed, in a previous study, that severity 
of underlying disease is a strong independent risk factor for 
CDAD.12 It is also likely to be a risk factor for severity of 
CDAD. 
C. difficile is not cultured routinely in microbiology lab-
oratories in Ireland; therefore, we have little historic infor-
mation with regard to the molecular epidemiology of C. dif-
ficile strains at our facility and at other Irish hospitals. This 
limitation means that we cannot predict when this strain type 
was introduced to our hospital or when it increased in fre-
quency. Limited historical strain typing from outbreaks of 
CDAD indicate that the earliest documentation of a PCRtype 
017 isolate in Ireland was in 1996, and the first record of this 
strain type at our hospital was in July 2001 (when 3 of 8 
samples were PCR type 017). Although our evidence is limited 
and is based on very small random-sample sizes, it does sug-
gest that this strain increased in frequency between 2001 and 
2003. After the present investigation, we identified this strain 
type in a number of other Irish hospitals.25'26 Unfortunately, 
C. difficile-positive status is shown only in a patient's medical 
record at a given healthcare facility, and this information is 
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not transmitted routinely when patients are transferred be-
tween facilities. This lack of epidemiological data makes it 
impossible to trace the emergence of this C. difficile clone 
throughout the greater Dublin area. 
Prior antibiotic use is an important individual risk factor 
for CDAD. Fluoroquinolone use has recently emerged as a 
predominant risk factor in epidemics in Pittsburgh, Penn-
sylvania, and Quebec, Canada.5,9 In April 2003, before the 
observed increase in CDAD, the antibiotic formulary had 
changed such that ofloxacin and benzyl penicillin were rec-
ommended as first-line agents for the treatment of CAP. Be-
fore this, in 2001 and the first 5 months of 2002, levofloxacin 
was used extensively in our hospital to treat CAP. This was 
switched to cefuroxime and clarithromycin in May 2002. The 
overall use of fluoroquinolones was halved in 2002 and did 
not alter significantly between 2002 and 2005. However, we 
speculate that use of levofloxacin, which accounted for almost 
half of the total use of fluoroquinolones in 2001 and 2002, 
may have promoted the acquisition of fluoroquinolone re-
sistance by C. difficile, leading to the emergence of this variant 
strain. Fluoroquinolone use continued in our hospital through-
out the outbreak, and despite this, the incidence of CDAD 
declined. However, the fluoroquinolones used were predom-
inantly older classes (eg, ofloxacin and ciprofloxacin) with 
lower antianaerobic activity than that of the newer classes of 
fluoroquinolones recently associated with increased risk of 
CDAD (levofloxcin and gatifloxacin).5'8'9 Although fluoro-
quinolones may have contributed to the emergence of this 
variant strain, we achieved control of this variant strain 
through much greater attention to infection control inter-
ventions, rather than through a change in the antibiotic use 
policy. 
Ongoing surveillance at our hospital indicates the persis-
tence of this toxin A-negative, toxin B-positive C. difficile 
strain, even though the incidence rate remains low. Recently, 
investigators have determined that greater sporulation capacity, 
along with increased antimicrobial resistance, may contribute 
to the persistence of certain nosocomial C. difficile isolates; 
however, the mechanisms by which the toxin A-negative, toxin 
B-positive strain persists have not yet been examined. The 
increased resistance to macrolide, lincosamide, and strepto-
gramin antibiotics as well as fluoroquinolones seen among 
the isolates in our outbreak is likely to contribute to their 
persistence in both the hospital environment and the human 
gut. Isolates from the 2 previously documented outbreaks of 
CDAD due to toxin A-negative, toxin B-positive strains do 
not appear to have been tested for fluoroquinolone resistance. 
However, as in the outbreak at our hospital, isolates from the 
outbreak in The Netherlands had an erm B gene that coded 
for clindamycin resistance.24 Surveillance after the outbreak 
in The Netherlands demonstrated that the toxin A-negative, 
toxin B-positive isolates did not persist, and those toxin A-
negative, toxin B-positive strains are no longer found at that 
institution (E. Kuijper, oral communication). 
In summary, we found that a C. difficile strain negative for 
toxin A and positive for toxin B and resistant to fluoroquin-
olones and macrolide, lincosamide, and streptogramin anti-
biotics is prevalent at our institution. Studies that address the 
molecular epidemiology and antibiotic susceptibility of C. 
difficile strains will help increase our understanding of the 
factors that lead to institutional outbreaks. The virulence fac-
tors associated with epidemic strain types must be precisely 
defined if the incidence of CDAD is to decline substantially. 
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